Form D · Biotechnology
Cellectar Biosciences, Inc.
Florham Park, NJ · CIK 0001279704
Offering snapshot reported Sep 22, 2023 · SEC filing
- Reported sold
- $24.5M Offering amount: $24.5M
- Investors reported
- 21 Form D · investor count
- Minimum accepted
- $84.4K Reported outside-investor minimum
- First sale
- Sep 8, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 22, 2023 | Initial | $24,500,000 | No comparison | 21 | SEC filing |
| Jan 8, 2021 | Initial | $20,499,993 | No comparison | 16 | SEC filing |
| May 31, 2019 | Initial | $5,045,000 | No comparison | 11 | SEC filing |
| Oct 13, 2017 | Initial | $7,766,164 | No comparison | 3 | SEC filing |
| Aug 15, 2014 | Initial | $617,500 | No comparison | 8 | SEC filing |
| Apr 14, 2011 | Initial | $5,134,903 | No comparison | 0 | SEC filing |
| Nov 19, 2009 | Amendment | $9,000,000 | $5,500,000vs Sep 9, 2009 | 1 | SEC filing |
| Sep 9, 2009 | Initial | $3,500,000 | No comparison | 1 | SEC filing |
| Feb 26, 2009 | Initial | $32,250,000 | No comparison | Not reported | SEC filing |
| Apr 18, 2005 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $1.37M
- Finders' fees
- $0
- Form D file number
- 021-492849
Includes shares of preferred stock to be issued upon exercise of warrants.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Oppenheimer & Co. Inc. | 249 |
Source: Form D, filed Sep 22, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Charles T. Bernhardt | Executive |
| Paul Berns | Director |
| James V. Caruso | Director, Executive |
| Asher Alban Chanan Kahn | Director |
| Michael J. Doyle | Director |
| Frederick W. Driscoll | Director |
| Dov Elefant | Executive |
| Simm Fass | Director |
| John Friend | Director |
| John E. Friend Ii | Executive |
| John P. Hamill | Executive |
| Kim Hawkins | Executive |
| Stephen A. Hill | Director |
| Chad J. Kolean | Executive |
| Darrell Shane Lea | Executive |
| Jarrod Longcor | Executive |
| Stefan D. Loren | Director |
| Thomas Rockwell Mackie | Director |
| James S. Manuso | Director |
| David B. Mc Williams | Director |
| John E. Neiderhuber | Director |
| John Neis | Director |
| Elias Nyberg | Executive |
| Harry S. Palmin | Director, Executive |
| Christopher J. Pazoles | Executive |
| Simon Pedder | Director, Executive |
| Joanne M. Protano | Executive |
| Howard M. Schneider | Director |
| Kristin C. Schuhwerk | Executive |
| Andrei Shustov | Executive |
| Douglas J. Swirsky | Director |
| Michael F. Tweedle | Director |
| Jamey P. Weichert | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
100 Campus Drive Suite 207
Florham Park, NJ, 07932
Florham Park, NJ, 07932